320 related articles for article (PubMed ID: 30176355)
21. Carbapenem-sparing beta-lactam/beta-lactamase inhibitors versus carbapenems for bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis.
Zhang H; Xu J; Xiao Q; Wang Y; Wang J; Zhu M; Cai Y
Int J Infect Dis; 2023 Mar; 128():194-204. PubMed ID: 36621752
[TBL] [Abstract][Full Text] [Related]
22. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study.
Harris PNA; Pezzani MD; Gutiérrez-Gutiérrez B; Viale P; Hsueh PR; Ruiz-Garbajosa P; Venditti M; Tumbarello M; Navarro-Francisco C; Calbo E; Akova M; Giamarellou H; Oliver A; Almirante B; Gasch O; Martínez-Martínez L; Schwaber MJ; Daikos G; Pitout J; Peña C; Hernández-Torres A; Doi Y; Pérez F; Tuon FF; Tacconelli E; Carmeli Y; Bonomo RA; Pascual Á; Paterson DL; Rodríguez-Baño J;
Int J Antimicrob Agents; 2017 Nov; 50(5):664-672. PubMed ID: 28782704
[TBL] [Abstract][Full Text] [Related]
23. Breakpoints for extended-spectrum beta-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations.
MacGowan A
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():166-8. PubMed ID: 18154541
[TBL] [Abstract][Full Text] [Related]
24. Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) infections: are carbapenem alternatives achievable in daily practice?
Pilmis B; Delory T; Groh M; Weiss E; Emirian A; Lecuyer H; Lesprit P; Zahar JR
Int J Infect Dis; 2015 Oct; 39():62-7. PubMed ID: 26327124
[TBL] [Abstract][Full Text] [Related]
25. A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.
Gutiérrez-Gutiérrez B; Pérez-Galera S; Salamanca E; de Cueto M; Calbo E; Almirante B; Viale P; Oliver A; Pintado V; Gasch O; Martínez-Martínez L; Pitout J; Akova M; Peña C; Molina J; Hernández A; Venditti M; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Giamarellou H; Almela M; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Natera C; Souli M; Bonomo RA; Carmeli Y; Paterson DL; Pascual A; Rodríguez-Baño J
Antimicrob Agents Chemother; 2016 Jul; 60(7):4159-69. PubMed ID: 27139473
[TBL] [Abstract][Full Text] [Related]
26. The prevalence and drug resistance pattern of extended spectrum β-lactamases (ESBLs) producing Enterobacteriaceae in Africa.
Saravanan M; Ramachandran B; Barabadi H
Microb Pathog; 2018 Jan; 114():180-192. PubMed ID: 29196174
[TBL] [Abstract][Full Text] [Related]
27. Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients.
Gutiérrez-Gutiérrez B; Rodríguez-Baño J
Clin Microbiol Infect; 2019 Aug; 25(8):932-942. PubMed ID: 30986558
[TBL] [Abstract][Full Text] [Related]
28. Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae.
Su J; Guo Q; Li Y; Wu S; Hu F; Xu S; Wang M
J Antimicrob Chemother; 2018 Nov; 73(11):3176-3180. PubMed ID: 30099554
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
Collins VL; Marchaim D; Pogue JM; Moshos J; Bheemreddy S; Sunkara B; Shallal A; Chugh N; Eiseler S; Bhargava P; Blunden C; Lephart PR; Memon BI; Hayakawa K; Abreu-Lanfranco O; Chopra T; Munoz-Price LS; Carmeli Y; Kaye KS
Antimicrob Agents Chemother; 2012 Apr; 56(4):2173-7. PubMed ID: 22290982
[TBL] [Abstract][Full Text] [Related]
30. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.
Rodríguez-Baño J; Gutiérrez-Gutiérrez B; Machuca I; Pascual A
Clin Microbiol Rev; 2018 Apr; 31(2):. PubMed ID: 29444952
[TBL] [Abstract][Full Text] [Related]
31. Risk associated with a systematic search of extended-spectrum β-lactamase-producing Enterobacteriaceae.
Prinapori R; Guinaud J; Khalil A; Lecuyer H; Gendrel D; Lortholary O; Nassif X; Viscoli C; Zahar JR
Am J Infect Control; 2013 Mar; 41(3):259-60. PubMed ID: 23062579
[TBL] [Abstract][Full Text] [Related]
32. Antimicrobial resistance in Enterobacteriaceae in Brazil: focus on β-lactams and polymyxins.
Sampaio JL; Gales AC
Braz J Microbiol; 2016 Dec; 47 Suppl 1(Suppl 1):31-37. PubMed ID: 27825605
[TBL] [Abstract][Full Text] [Related]
33. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs).
Paterson DL
Clin Microbiol Infect; 2000 Sep; 6(9):460-3. PubMed ID: 11168179
[TBL] [Abstract][Full Text] [Related]
34. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
Nguyen HM; Shier KL; Graber CJ
J Antimicrob Chemother; 2014 Apr; 69(4):871-80. PubMed ID: 24265230
[TBL] [Abstract][Full Text] [Related]
35. Extended-spectrum β-lactamase-producing Enterobacteriaceae, national study of antimicrobial treatment for pediatric urinary tract infection.
Lagree M; Bontemps S; Dessein R; Angoulvant F; Madhi F; Martinot A; Cohen R; Dubos F;
Med Mal Infect; 2018 May; 48(3):193-201. PubMed ID: 29449049
[TBL] [Abstract][Full Text] [Related]
36. Extended-spectrum beta-lactamase-producing organisms.
Falagas ME; Karageorgopoulos DE
J Hosp Infect; 2009 Dec; 73(4):345-54. PubMed ID: 19596491
[TBL] [Abstract][Full Text] [Related]
37. beta-Lactams without a suicide inhibitor.
Giamarellou H
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():194-7. PubMed ID: 18154547
[TBL] [Abstract][Full Text] [Related]
38. [Extended-spectrum beta-lactamase producing-enterobacteriaceae].
Mariani-Kurkdjian P; Doit C; Bingen E
Arch Pediatr; 2012 Nov; 19 Suppl 3():S93-6. PubMed ID: 23178141
[TBL] [Abstract][Full Text] [Related]
39. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae.
Balakrishnan I; Awad-El-Kariem FM; Aali A; Kumari P; Mulla R; Tan B; Brudney D; Ladenheim D; Ghazy A; Khan I; Virgincar N; Iyer S; Carryn S; Van de Velde S
J Antimicrob Chemother; 2011 Nov; 66(11):2628-31. PubMed ID: 21810837
[TBL] [Abstract][Full Text] [Related]
40. Ertapenem susceptibility of extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care centre in India.
Behera B; Mathur P; Das A; Kapil A
Singapore Med J; 2009 Jun; 50(6):628-32. PubMed ID: 19551319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
